The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy^*

References

• Bleyer A, Viny A, Barr R. Cancer in 15- to 29-year-olds by primary site. The Oncologist. 2006;11:590–601.
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Boll B, Diehl V. Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectives. Expert Opin Pharmacother. 2014;15:1139–1151.
   PubMed Web of Science ®Google Scholar
• Venkataraman G, Mirza MK, Eichenauer DA, et al. Current status of prognostication in classical Hodgkin lymphoma. Br J Haematol. 2014;165:287–299.
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339:1506–1514.
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Shrestha R, Castillo JJ. Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: analysis of the National Cancer Data Base. J Clin Oncol. 2015;33:625–633.
   PubMed Web of Science ®Google Scholar
• Moccia AA, Donaldson J, Chhanabhai M, et al. International Prognostic Score in advanced-stage Hodgkin’s lymphoma: altered utility in the modern era. J Clin Oncol. 2012;30:3383–3388.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372:311–319.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Ribrag V, Michot J-M, et al. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a Phase 1b Study (KEYNOTE-013). Blood. 2014;124:290.
   Web of Science ®Google Scholar
• Coppleson LW, Rappaport H, Strum SB, et al. Analysis of the Rye classification of Hodgkin’s disease. The prognostic significance of cellular composition. J Natl Cancer Inst. 1973;51:379–390.
   PubMedGoogle Scholar
• Colby TV, Hoppe RT, Warnke RA. Hodgkin's disease: a clinicopathologic study of 659 cases. Cancer. 1982;49:1848–1858.
   PubMed Web of Science ®Google Scholar
• Ree HJ, Kadin ME. Macrophage-histiocytes in Hodgkin's disease. The relation of peanut-agglutinin-binding macrophage-histiocytes to clinicopathologic presentation and course of disease. Cancer. 1985;56:333–338.
   PubMed Web of Science ®Google Scholar
• Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362:875–885.
   PubMed Web of Science ®Google Scholar
• Steidl C, Farinha P, Gascoyne RD. Macrophages predict treatment outcome in Hodgkin's lymphoma. Haematologica. 2011;96:186–189.
   PubMed Web of Science ®Google Scholar
• Sanchez-Espiridion B, Montalban C, Lopez A, et al. A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. Blood. 2010;116:e12–e17.
   PubMed Web of Science ®Google Scholar
• Greaves P, Clear A, Coutinho R, et al. Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol. 2013;31:256–262.
   PubMed Web of Science ®Google Scholar
• Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011;29:1812–1826.
   PubMed Web of Science ®Google Scholar
• Greaves P, Clear A, Owen A, et al. Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood. 2013;122:2856–2863.
   PubMed Web of Science ®Google Scholar
• Nomura T, Sakaguchi S. Naturally arising CD25 + CD4+ regulatory T cells in tumor immunity. Curr Top Microbiol Immunol. 2005;293:287–302.
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Salvado MT, et al. Outcome in Hodgkin’s lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005;11:1467–1473.
   PubMed Web of Science ®Google Scholar
• Mullen AC, High FA, Hutchins AS, et al. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science. 2001;292:1907–1910.
   PubMed Web of Science ®Google Scholar
• Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood. 2008;112:1557–1569.
   PubMed Web of Science ®Google Scholar
• Stein H, Poppema S, Delsol G, et al. WHO classification of tumors of hematopoietic and lymphoid tissues. Hodgkin lymphoma. Geneva, Switzerland: WHO Press; 2008. p. 321–334.
   Google Scholar
• Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol. 1989;7:1630–1636.
   PubMed Web of Science ®Google Scholar
• Escobar IG, Barrigon DC, Tamayo P, et al. Prognostic impact of pretransplantation computed tomography and gallium scans in patients with Hodgkin lymphoma with poor prognosis undergoing hematopoietic stem cell transplantation. Clin Lymph Myeloma. 2006;7:217–225.
   PubMedGoogle Scholar
• Barrington SF, Mackewn JE, Schleyer P, et al. Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. Ann Oncol. 2011;22:739–734.
   PubMed Web of Science ®Google Scholar
• Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015;372:1598–1607.
   PubMed Web of Science ®Google Scholar
• Labrador J, Cabrero-Calvo M, Perez-Lopez E, et al. ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma. Ann Hematol. 2014;93:1745–1753.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Cheson BD. Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol. 2015;4:5.
   PubMed Web of Science ®Google Scholar
• Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348:2386–2395.
   PubMed Web of Science ®Google Scholar
• Maillo A, Diaz P, Blanco A, et al. Proportion of S-phase tumor cells measured by flow cytometry is an independent prognostic factor in meningioma tumors. Cytometry. 1999;38:118–123.
   PubMedGoogle Scholar
• Sanchez ML, Almeida J, Vidriales B, et al. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation. Leukemia. 2002;16:1460–1469.
   PubMed Web of Science ®Google Scholar
• Barrena S, Almeida J, Del CG-M, et al. Flow cytometry immunophenotyping of fine-needle aspiration specimens: utility in the diagnosis and classification of non-Hodgkin lymphomas. Histopathology. 2011;58:906–918.
   PubMed Web of Science ®Google Scholar
• Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561–577.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assn. 1958;53:457–481.
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–170.
   PubMedGoogle Scholar
• Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34:187–220.
   Google Scholar
• “Student” [Gosset WS]. The probable error of a mean. Biometrika. 1908;6:1.
   Web of Science ®Google Scholar
• Yates F. Contingency table involving small numbers and the χ2 test. Suppl J R Stat Soc. 1934;1:217–235.
   Google Scholar
• Fisher RA. On the interpretation of χ2 from contingency tables, and the calculation of P. J R Stat Soc. 1922;85:87–94.
   Google Scholar
• Kuppers R. New insights in the biology of Hodgkin lymphoma. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program 2012; 2012. p. 328–334.
   Google Scholar
• Di Gaetano R, Gasparetto V, Padoan A, et al. Flow cytometry CD4(+)CD26(−)CD38(+) lymphocyte subset in the microenvironment of Hodgkin lymphoma-affected lymph nodes. Ann Hematol. 2014;93:1319–1326.
   PubMed Web of Science ®Google Scholar
• Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268–3277.
   PubMed Web of Science ®Google Scholar
• Yamamoto R, Nishikori M, Kitawaki T, et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood. 2008;111:3220–3224.
   PubMed Web of Science ®Google Scholar
• Borchmann P. Early intensification treatment approach in advanced-stage Hodgkin lymphoma. Hematol/Oncol Clin North Am. 2014;28:65–74.
   PubMed Web of Science ®Google Scholar
• Evens AM, Kostakoglu L. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. Blood. 2014;124:3356–3364.
   PubMed Web of Science ®Google Scholar
• Ansell SM. Induction therapy for advanced-stage Hodgkin lymphoma: late intensification (ABVD chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant only for those who relapse). Hematol/Oncol Clin North Am. 2014;28:75–86.
   PubMed Web of Science ®Google Scholar
• Kalina T, Flores-Montero J, Lecrevisse Q, et al. Quality assessment program for EuroFlow protocols: summary results of four-year (2010–2013) quality assurance rounds. Cytometry A. 2015;87:145–156.
   PubMed Web of Science ®Google Scholar